Myriad: Keeping a low profile
The latest rulings in the controversial legal battle over breast cancer gene patents seem to have found two out of three issues in defendant Myriad Genetics’ favour, but legal counsel Ben Jackson isn’t too excited by the implications.
A step forward: new dosage patents in Mexico?
The status of patentability for new dosage regimes in Mexico is unclear, but there have been some positive signs, says Pablo Fuentes.
On the right track: the road to innovation in Brazil
Brazil’s IP system has struggled to keep pace with its economic growth, but as Otto Licks and Marcela Trigo explain, there are some promising signs.
A question of fairness: preliminary injunctions in Mexico
The system governing preliminary injunctions for pharmaceutical patent infringement should be revised to stave off potential frivolous cases, say Hedwig Lindner and Manuel Morante.
The right foundations: the importance of prior art searches
LSIPR talks to Matt McBride about how Science IP can help businesses ensure their patent plans get off to the best possible start.
Crossed wires: protecting medicines in Mexico
When introducing medicinal products to any market, the strength of the trademark is crucial. But the Mexican system requires getting trademark approval from two different authorities.
A changing landscape: life sciences in Russia
Russia’s life sciences industry is growing rapidly, say Vadim Chagin and Maria Nilova.
A step into the unknown: India's first compulsory licence
For the first time in the history of the Indian patent system, a compulsory licence has been granted. Archana Shanker considers the implications.
Reaching out: BIO abroad
For the Biotechnology Industry Organization, key developing markets pose particular challenges in terms of IP and also in a wider context. LSIPR spoke to Joe Damond and Lila Feisee about international affairs.
Out in front: the Boston cluster
When it comes to life sciences, Boston is out on its own. LSIPR takes a look at innovation in the Olde Towne.
